Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

LENZ Therapeutics, Inc. Director's Dealing 2021

Jun 29, 2021

32045_dirs_2021-06-28_320979b1-a122-4ed7-8a36-9822a5e17da9.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Graphite Bio, Inc. (GRPH)
CIK: 0001815776
Period of Report: 2021-06-24

Reporting Person: Carlo Rizzuto (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-06-24 Stock Option (right to buy) $17.00 A 40000 Acquired 2031-06-23 Common Stock (40000) Direct

Footnotes

F1: 1/36th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of June 24, 2021, subject to the Reporting Person's continuous service to the Issuer on each such date.